Factor XI Measurement in Acute Coronary Syndrome

Diana A. Gorog; Young-Hoon Jeong

doi:10.1055/a-2546-2581

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2025; 125(09): 905-907
DOI: 10.1055/a-2546-2581

Invited Editorial Focus

Factor XI Measurement in Acute Coronary Syndrome

Authors

Diana A. Gorog

¹Faculty of Medicine, National Heart and Lung Institute, Imperial College, London, United Kingdom

²Centre for Health Services and Clinical Research, Postgraduate Medical School, University of Hertfordshire, Hatfield, Hertfordshire, United Kingdom

³East and North Hertfordshire NHS Trust, Hertfordshire, United Kingdom

⁴School of Cardiovascular and Metabolic Medicine and Sciences, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom
Young-Hoon Jeong

⁵Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Republic of Korea

⁶CAU Thrombosis and Biomarker Center, Chung-Ang University Gwangmyeong Hospital, Gwangmyeong, Republic of Korea

Abstract

Full Text

References

References
1 Preis M, Hirsch J, Kotler A. et al. Factor XI deficiency is associated with lower risk for cardiovascular and venous thromboembolism events. Blood 2017; 129 (09) 1210-1215
2 Doggen CJM, Rosendaal FR, Meijers JCM. Levels of intrinsic coagulation factors and the risk of myocardial infarction among men: opposite and synergistic effects of factors XI and XII. Blood 2006; 108 (13) 4045-4051
3 Folsom AR, George KM, Appiah D. Lack of association of plasma factor XI with incident stroke and coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) Study. Atherosclerosis 2015; 243 (01) 181-185
4 Olson NC, Cushman M, Judd SE. et al. Associations of coagulation factors IX and XI levels with incident coronary heart disease and ischemic stroke: the REGARDS study. J Thromb Haemost 2017; 15 (06) 1086-1094
5 Rohmann JL, Huo S, Sperber PS. et al. Coagulation factor XII, XI, and VIII activity levels and secondary events after first ischemic stroke. J Thromb Haemost 2020; 18 (12) 3316-3324
6 Chen H, Shen M, Niu R. et al. Associations of coagulation factor X and XI with incident acute coronary syndrome and stroke: a nested case-control study. J Thromb Haemost 2021; 19 (11) 2781-2790
7 Loeffen R, van Oerle R, de Groot PG. et al. Increased factor XIa levels in patients with a first acute myocardial infarction: the introduction of a new thrombin generation based factor XIa assay. Thromb Res 2014; 134 (06) 1328-1334
8 Aarsetøy R, Ten Cate H, Spronk H. et al. Activated factor XI-antithrombin complex presenting as an independent predictor of 30-days mortality in out-of-hospital cardiac arrest patients. Thromb Res 2021; 204: 1-8
9 Lee SH, Kim HK, Ahn J-H. et al. Prognostic impact of hypercoagulability and impaired fibrinolysis in acute myocardial infarction. Eur Heart J 2023; 44 (19) 1718-1728
10 Ząbczyk M, Ariëns RAS, Undas A. Fibrin clot properties in cardiovascular disease: from basic mechanisms to clinical practice. Cardiovasc Res 2023; 119 (01) 94-111
11 Gorog DA, Lip GYH. Impaired spontaneous/endogenous fibrinolytic status as new cardiovascular risk factor?: JACC review topic of the week. J Am Coll Cardiol 2019; 74 (10) 1366-1375
12 Kanji R, Gue YX, Memtsas V, Spencer NH, Gorog DA. Biomarkers of thrombotic status predict spontaneous reperfusion in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol 2023; 81 (19) 1918-1932
13 Mega JL, Braunwald E, Wiviott SD. et al; ATLAS ACS 2–TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366 (01) 9-19
14 Yu J, Wang T, Zhang X. et al. Anti-thrombotic effects mediated by a novel dual-target peptide inhibiting both platelet aggregation and thrombin activity without causing bleeding. Thromb Haemost 2024; 124 (02) 108-121
15 Goto S, Goto S. Dual antiplatelet therapy or dual pathway inhibition. Thromb Haemost 2024; 124 (03) 274-276
16 Galli M, Laborante R, Ortega-Paz L. et al. Factor XI inhibitors in early clinical trials: a meta-analysis. Thromb Haemost 2023; 123 (06) 576-584
17 Rao SV, Kirsch B, Bhatt DL. et al; PACIFIC AMI Investigators. A multicenter, phase 2, randomized, placebo-controlled, double-blind, parallel-group, dose-finding trial of the oral factor XIa inhibitor asundexian to prevent adverse cardiovascular outcomes after acute myocardial infarction. Circulation 2022; 146 (16) 1196-1206
18 Piccini JP, Patel MR, Steffel J. et al; OCEANIC-AF Steering Committee and Investigators. Asundexian versus apixaban in patients with atrial fibrillation. N Engl J Med 2025; 392 (01) 23-32